Understanding Estrogen Receptor Positive Breast Cancer in 2025

Did you know that estrogen receptor positive breast cancer, making up about two-thirds of cases, is uniquely influenced by hormone activity? This article explores current treatment methods, hormone therapy options, emerging therapies, and dietary considerations relevant to managing this condition.

Hormone Therapy for ER-Positive Breast Cancer

Hormone therapy is designed specifically for breast cancers that have hormone receptors: estrogen receptors (ER) and/or progesterone receptors (PR). These receptors enable the cancer cells to use hormones to fuel growth.

How Hormone Therapy Works

Blocking estrogen: Drugs like tamoxifen block estrogen molecules from attaching to cancer cells.
Lowering estrogen production: Aromatase inhibitors (AIs) such as letrozole, anastrozole, and exemestane reduce estrogen production, especially effective after menopause when estrogen is mainly produced in fat tissue.
Degrading estrogen receptors: Newer drugs like selective estrogen receptor degraders (SERDs), including fulvestrant and emerging PROTAC SERDs (such as vepdegestant), actively break down estrogen receptors on cancer cells.

When Hormone Therapy is Used

As adjuvant therapy post-surgery (including after lumpectomy) to reduce recurrence risk, usually taken for 5 to 10 years depending on the patient’s risk profile.
As neoadjuvant therapy before surgery to shrink tumors.
For metastatic or advanced cancer to control disease progression.

Treatment Duration

Typically, hormone therapy is administered for at least 5 years. For women with higher recurrence risk, treatment may extend to 10 years or more, guided in part by genomic testing (e.g., Breast Cancer Index).

Aromatase Inhibitors and Letrozole Use in Women Over 70

Effectiveness and Considerations

Aromatase inhibitors (AIs) such as letrozole are the preferred hormone therapy for postmenopausal women, including elderly patients aged 70 and above. They effectively lower estrogen levels by blocking the aromatase enzyme responsible for converting androgens to estrogen in fat tissue.

Side Effects in Elderly Women

Bone thinning and osteoporosis: AIs can lead to reduced bone density, increasing fracture risk. Regular bone density monitoring is essential.
Muscle and joint pain: These are common but sometimes manageable by switching to a different AI, using medications like duloxetine, or employing exercise and NSAIDs.
Management: Bone-strengthening agents such as bisphosphonates (e.g., zoledronic acid) or denosumab are often given to counteract bone loss.

Elderly patients should have individualized treatment plans considering comorbidities, bone health, and quality of life.

Hormonal Therapy after Lumpectomy

Following breast-conserving surgery (lumpectomy), hormone therapy is commonly used in hormone receptor-positive breast cancer to reduce the risk of recurrence.

Postmenopausal women: Aromatase inhibitors are typically prescribed for 5 to 10 years.
Premenopausal women: Tamoxifen is most common; ovarian suppression combined with aromatase inhibitors may be used in higher-risk cases.

Hormone therapy has been shown in clinical studies to improve survival and decrease local and distant recurrences after surgery.

Considering Chemotherapy in Hormone Receptor-Positive Breast Cancer

Chemotherapy is not always required for hormone receptor-positive breast cancer, especially in early-stage cancers with a favorable prognosis. For low-risk patients, hormone therapy alone often suffices.

Chemotherapy may be recommended when:

Tumor size or grade is high
Lymph nodes are involved
Genomic tests indicate a higher risk of recurrence
The cancer is advanced or aggressive

Oncologists tailor chemotherapy decisions based on tumor biology and overall patient health.

Advances in Treatments in 2025

Recent developments in hormone receptor-positive breast cancer therapies include:

PROTAC SERDs: Vepdegestant, an oral SERD, has demonstrated improvements in progression-free survival for metastatic, ESR1-mutated hormone receptor-positive breast cancer compared to fulvestrant in clinical studies. It offers a potential treatment option for patients with resistance to existing therapies.
Camizestrant: Clinical trials have indicated benefits when switching to camizestrant from aromatase inhibitors upon ESR1 mutations in metastatic breast cancer. It is pending regulatory approval.
Combination targeted therapies: The combination of inavolisib with palbociclib and fulvestrant has been shown to extend overall survival and delay the need for chemotherapy in advanced PIK3CA-mutated hormone receptor-positive breast cancers.
Symptom management: Elinzanetant, a neurokinin receptor antagonist, is under study for reducing hot flashes without impacting cancer therapies, potentially improving quality of life.

Diet and Lifestyle Considerations

Diet can play a supportive role in managing breast cancer. Recent research suggests:

Moderating red meat intake: Consumption of more than 2.5 ounces (70 grams) of red meat daily has been associated with higher breast cancer mortality risk. Reducing red meat intake may be beneficial as part of an overall healthy diet.
A balanced, plant-rich diet is generally recommended, although no specific foods beyond red meat have conclusive contraindications.
Physical activity: Regular exercise is encouraged to help manage hormone therapy side effects, support bone health, and enhance well-being.

Managing Hormone Therapy Side Effects in Older Women

Hormone therapy may cause menopausal symptoms such as hot flashes, vaginal dryness, and joint discomfort, which can impact quality of life, particularly in women aged 70 and older.

Hot flashes: Non-hormonal treatments like elinzanetant are being evaluated to safely alleviate hot flashes without interfering with cancer treatment.
Vaginal symptoms: Vaginal estrogen therapy may be used cautiously under physician guidance; recent studies suggest it can be safe for some breast cancer survivors.
Bone health: Ongoing monitoring and preventive therapies help reduce fracture risk.
Supportive care: Physical activity and management strategies contribute to improved quality of life.

Factors Contributing to Breast Cancer Development

Breast cancer arises from multiple factors including:

Genetic mutations (such as BRCA1/2)
Hormonal influences, especially estrogen and progesterone in hormone receptor-positive cancers
Environmental and lifestyle factors
Age and other biological variables

While hormone receptor-positive tumors grow due to estrogen binding, treatment targets this pathway but does not reverse the underlying genetic changes that initiated cancer formation. Research continues to further elucidate these complex causes.

Summary

Estrogen receptor-positive breast cancer treatment in 2025 focuses on hormone therapy aimed at slowing cancer growth and reducing recurrence risk. Aromatase inhibitors remain a key treatment for postmenopausal women, including patients over 70, with attention to bone health and side effect management. Hormone therapy is standard after breast-conserving surgery and may permit avoiding chemotherapy in select low-risk patients. Emerging therapies such as PROTAC SERDs and targeted kinase inhibitors show promise for advanced disease. Dietary adjustments and physical activity support overall patient outcomes. Continued research into breast cancer origins guides evolving prevention and treatment strategies.

Sources

Disclaimer: All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. The information and materials contained in these pages and the terms, conditions and descriptions that appear, are subject to change without notice.

Lifestyle